![Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/8f767690-0d1e-4ee9-a9f0-bac2519da55f/gr1.gif)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
![Mount Sinai Team Offers Additional Data on Efficacy of Blood Thinners for COVID-19 and Insight on Best Potential Regimens | Mount Sinai - New York Mount Sinai Team Offers Additional Data on Efficacy of Blood Thinners for COVID-19 and Insight on Best Potential Regimens | Mount Sinai - New York](https://www.mountsinai.org/files/MSHealth/Assets/Global/Newsroom/F2Prophylactic-therapeutic-association-Newsroom-770x420.jpg)
Mount Sinai Team Offers Additional Data on Efficacy of Blood Thinners for COVID-19 and Insight on Best Potential Regimens | Mount Sinai - New York
![Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7013e3_COVIDVaccineFieldEffectiveness_IMAGE_29Mar21_v2_1200x627.jpg?_=23735)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December
![Pfizer Inc. on Twitter: "BREAKING: Along with @BioNTech_Group, we shared updated data from a Phase 2/3 study of our #COVID19 vaccine in children 6 mos through 4 yrs. Learn more about these Pfizer Inc. on Twitter: "BREAKING: Along with @BioNTech_Group, we shared updated data from a Phase 2/3 study of our #COVID19 vaccine in children 6 mos through 4 yrs. Learn more about these](https://pbs.twimg.com/media/Fa1y6aCWAAIKYxf.jpg)